CEP290 and respiratory distress syndrome in premature infants: Tailored for CEP290-associated IRDs such as LCA10, EDIT-101 is a CRISPR/Cas9-based gene editing therapy developed by Editas Medicine to excise the aberrant splice donor generated by the IVS26 mutation and thereby restore normal CEP290 expression.